人福醫藥(600079.SH):人福利康通過美國FDA認證
格隆匯1月14日丨人福醫藥(600079.SH)公佈,近日,公司子公司武漢人福利康藥業有限公司(以下簡稱“人福利康”,公司持有其67.33%的股權,根據增資協議的遠期回購約定,公司持有其100%權益)收到美國食品藥品監督管理局(FDA)的通知,人福利康口服固體制劑車間通過了美國FDA認證。
本次FDA認證涉及公司全資子公司Epic Pharma, LLC計劃將部分產品的生產業務轉移至人福利康的口服固體制劑車間。該口服固體制劑車間位於武漢市東湖新技術開發區神墩二路98號,主要生產片劑、硬膠囊劑型的藥品,設計產能為10億片(粒)/年,人福利康對本次FDA認證的累計投入約為人民幣500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.